• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Unknown Causes of Death in Cancer Patients
CONCLUSION: Of the patients, 7.4% died of unknown causes during follow-up and the proportion of death was higher with longer follow-up and among more indolent cancers. The attribution of high percentages of unknown COD to cancer or non-cancer causes could impact population-based cancer registry studies or clinical trial outcomes with respect to measures involving CSS and mortality.PMID:37038261 | DOI:10.1097/COC.0000000000001003
Source: Clinical Prostate Cancer - April 11, 2023 Category: Cancer & Oncology Authors: Siven Chinniah Mckenzee Chiam Kyle Mani Menglu Liang Daniel M Trifiletti Daniel E Spratt Vinayak K Prasad Ming Wang Leila T Tchelebi Nicholas G Zaorsky Source Type: research

Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk
CONCLUSIONS: Compared with GnRH agonists, the GnRH antagonist was found to be associated with a decreased risk of HF, specifically among patients with prior CVD. Among those with no prior CVD, the GnRH antagonist was associated with a decreased risk of IHD but an increased risk of arrhythmia.PMID:36791755 | DOI:10.6004/jnccn.2022.7083
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 15, 2023 Category: Cancer & Oncology Authors: Alice Dragomir Nawar Touma Jason Hu Sylvie Perreault Armen G Aprikian Source Type: research

ADT Use for Prostate Cancer Linked to Increased Risk for CVD Death
Risk increased for CVD death and for death from ischemic heart disease and stroke, especially among those aged 70 to 79 years
Source: The Doctors Lounge - Oncology - July 29, 2022 Category: Cancer & Oncology Tags: Cardiology, Internal Medicine, Oncology, Pharmacy, Urology, Geriatrics, Journal, Source Type: news

Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients
CONCLUSION: Our study provides knowledge on abiraterone and enzalutamide real-life safety profiles, especially for events leading to hospitalisation. Despite several limitations, including the lack of clinical data, the safety signal for AKI under abiraterone is in line with results of an analysis of the French pharmacovigilance database, which requires further specific investigations. Enlightening the clinicians' therapeutic choices for patients treated for prostate cancer, our study should lead to clinicians to be cautious in the use of abiraterone.PMID:34224605 | DOI:10.1111/bcp.14972
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Lucie-Marie Scailteux Fabien Despas Fr édéric Balusson Boris Campillo-Gimenez Romain Mathieu S ébastien Vincendeau Andr é Happe Emmanuel Nowak Sandrine Kerbrat Emmanuel Oger Source Type: research

Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients: an asian population-based observational study
Conclusions: The current study based on Asian population suggests that treatment with neither GnRH agonist nor antiandrogens increases the risk of cardio-cerebrovascular disease compared to patients with ADT-naïve prostate cancer.
Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Jong-Mi Seong, Dongho Shin, Jae Woo Sung, Shinjay Cho, Jonghyup Yang, Sungmin Kang, Hyong Woo Moon, Kyu Won Lee, U-Syn Ha Tags: Research Paper Source Type: research

Omega-3 fats do not protect against cancer
(University of East Anglia) Omega-3 fats do not protect against cancer -- according to new University of East Anglia research. Increased consumption of omega-3 fats is widely promoted globally because of a common belief that it will protect against, or even reverse, diseases such as cancer, heart attacks and stroke. But two systematic reviews find that omega-3 supplements may slightly reduce coronary heart disease mortality and events, but slightly increase risk of prostate cancer. Both beneficial and harmful effects are small.
Source: EurekAlert! - Cancer - February 28, 2020 Category: Cancer & Oncology Source Type: news

Lifestyle factors and prostate-specific antigen (PSA) testing in UK Biobank: Implications for epidemiological research
Conclusions A variety of sociodemographic, lifestyle and health-related characteristics are associated with PSA testing, suggesting that observed associations of some of these traits with risk for prostate cancer in epidemiological studies may be, at least partially, due to detection bias.
Source: Cancer Epidemiology - September 29, 2016 Category: Cancer & Oncology Source Type: research

Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study Epidemiology
Conclusion The magnitude of subsequent CVD risk varies according to cancer subtype and by the presence of CVRFs. Overall survival in survivors who develop CVD is poor, emphasizing the need for targeted prevention strategies for individuals at highest risk of developing CVD.
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Armenian, Xu, Ky, Sun, Farol, Pal, Douglas, Bhatia, Chao Tags: Population and observational studies (SEER, WHI observational, etc.) Epidemiology Source Type: research

Pages: 1  2